Addressing Developmental Challenges of Gene Therapy Viral Vectors

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, Trends in Formulation, October 2022
Volume 2022 eBook
Issue 3
Pages: 36–40

Significant improvements have been developed to tackle the challenges in viral vector manufacturing at each stage.

Sveta/Stock.adobe.com – Advances in technologies are being used to enhance the manufacturing of viral vectors for gene therapies at each step of the manufacturing process.

Sveta/Stock.adobe.com

Gene therapy has rapidly expanded conceptually and technically, now covering a wide array of tools and methods, including the advancement of viral vector delivery for gene therapies. Lentiviral vectors and adeno-associated virus (AAV) are two primary delivery mechanisms of gene therapies. While versatile and robust, there are some inherent weaknesses in the production of both AAV and lentivirus vectors, and, as a result, production is not well optimized. Over time, significant improvements have been developed to facilitate the manufacture of these viral vectors at each stage.

Read this article in Pharmaceutical Technology’s October 2022 Trends in Formulation eBook.

About the authors

Ger Brophy, is the executive vice-president of Biopharma Production, Arvind Srivastava is a technical fellow, Bioprocessing, and Greg Swan is business development manager for Cell & Gene Therapy; all are at Avantor.

Article Details

Pharmaceutical Technology
eBook: Trends in Formulation, October 2022
October 2022
Pages: 36–40

Citation

When referring to this article, please cite it as G. Brophy, A. Srivastava, and G.Swan, “Addressing Developmental Challenges of Gene Therapy Viral Vectors," Pharmaceutical Technology Trends in Formulation eBook (October 2022).

Articles in this issue
Small is a Powerful Ingredient for Patient-Centric Formulations
Small is a Powerful Ingredient for Patient-Centric Formulations
Kalyakan/Stock.adobe.com – optimizing early drug candidate screening can save time and shorten drug discovery and development timelines.
Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk
Sveta/Stock.adobe.com – Advances in technologies are being used to enhance the manufacturing of viral vectors for gene therapies at each step of the manufacturing process.
Addressing Developmental Challenges of Gene Therapy Viral Vectors
Improved Formulations to Enable Stable Delivery of Biologics
Improved Formulations to Enable Stable Delivery of Biologics
Nitrosamides–Should They Be Treated the Same as Nitrosamines?
Nitrosamides–Should They Be Treated the Same as Nitrosamines?
Emerging Applications of Vitamin E TPGS in Drug Delivery
Emerging Applications of Vitamin E TPGS in Drug Delivery
Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines, episode 7
Behind the Headlines episode 6
Behind the Headlines episode 5
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk to Establish New Production Facility for Rare Disease Therapies in Denmark with DKK 8.5 Billion Investment

Feliza Mirasol
December 17th 2024
Article

Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Novo Nordisk Gains Manufacturing Sites from Novo Holdings and Novavax while EC Approves Catalent Acquisition

Feliza Mirasol
December 11th 2024
Article

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

Gary Ritchie;Sharon Flank
December 10th 2024
Article

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.